Dr. Grill has been the recipient of the National Alzheimer’s Coordinating Center Junior Investigator Award, the Alzheimer’s Association Turken Research Prize, the Community Spirit Award from OPICA Adult Day Services, and the P. Gene and Elaine Smith Term Chair in Alzheimer’s Disease Research. He has been funded by the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, the Alzheimer’s Association, the Hartford Foundation, the BrightFocus Foundation, the American Federation for Aging Research, and the University of California. He is the co-leader of the Recruitment Unit and the Internal Ethics Committee for the NIH-funded Alzheimer’s Clinical Trial Consortium. He is a member of the Scientific Advisory Board for Maria Shriver’s Women’s Alzheimer’s Movement and for Lauren Rogen Miller and Seth Rogan's HfC. In 2017, he co-chaired a workgroup as part of the NIH’s Inclusion Across the Lifespan workshop, a congressional mandate in the 21st Century Cures Act (P.L. 114-255). He was part of a working group sponsored by the National Institute on Aging and the Alzheimer’s Association charged with creating a national strategy for recruitment to Alzheimer’s disease clinical research.
Areas of Expertise (5)
Recruitment and Retention
Community Spirit Award (professional)
OPICA Adult Day Services
Junior Investigator Award (professional)
National Alzheimer’s Coordinating Center
Turken Research Prize (professional)
P. Gene and Elaine Smith Term Chair (professional)
Alzheimer’s Disease Research
Wake Forest University School of Medicine: PhD, Neuroscience 2004
Media Appearances (5)
Former California First Lady Maria Shriver gives UC Irvine gender-related research on Alzheimer’s disease another boost
The Orange County Register online
Her organization’s outreach included Shriver’s presence in November at the opening of a senior living and memory care center in Redondo Beach, an appearance highlighted by a Q&A with leading researchers that included UCI MIND’s director, Dr. Joshua Grill.
Should Alzheimer's Prevention Trials Include Disease-Modifying Therapies? Experts Weigh the Risks and Benefits
Neurology Today online
“The evidence suggesting problematic safety profiles for BACE inhibitors is mounting. Yet, there are still more questions than answers about BACE inhibitors, especially in preclinical AD,” Joshua Grill, PhD, associate director of the Alzheimer's Disease Research Center and director of the Institute for Memory Impairments and Neurological Disorders at the University of California in Irvine, told Neurology Today.
Don't Be Taken In by Dementia 'Pseudomedicine'
In addition, there's concern that by falling for pseudomedicine, people are delaying the care they truly need. “A common situation is an older adult becoming concerned about their memory and taking a supplement to try to ward off dementia,” says Joshua Grill, director of the Institute for Memory Impairments and Neurological Disorders at the University of California, Irvine. “But in reality, if they saw their doctor, they might find out that another medical condition such as hypothyroidism, or a certain prescription medication, is causing symptoms and can be easily treated. They're just making things worse.”
What America's Corporations Can Do To Tackle Alzheimer's
This past week, thousands of the world's leading Alzheimer's disease researchers gathered in London to discuss and debate the latest research. Among the questions that captured much attention was: what's the right kind of study to discover the best treatments?
Alzheimer’s research ramps up
UCI News online
And under the leadership of Joshua Grill, co-director of UCI MIND and associate professor of psychiatry & human behavior, the institute’s portfolio of clinical trials to identify new preventions or cures is growing.
Michelle M. Nuño, Daniel L. Gillen, Joshua D. Grill & for the Alzheimer’s Disease Cooperative Study
2019 Alzheimer’s disease (AD) clinical trials require enrollment of a participant and a study partner, whose role includes assessing participant cognitive and functional performance. AD trials now investigate early stages of the disease, when participants are not cognitively impaired. This gives rise to the question of whether study partners or participants provide more information in these trials.
Mary M. Ryan, Joshua D. Grill, Daniel L. Gillen & for the Alzheimer’s Disease Neuroimaging Initiative
2019 Preclinical Alzheimer’s disease (AD) clinical trials require participants to enroll with a study partner, a person who can attend visits and report changes in the participant’s cognitive ability. Whether study partners, compared to participants themselves, provide added information about participant cognition in preclinical AD trials is an open question. We tested the hypothesis that study partners provide meaningful information related to participant cognition cross-sectionally and longitudinally, and assessed whether amyloid status modified observed effects.
Joshua D. Grill, Chelsea G. Cox, Kristin Harkins & Jason Karlawish
2019 The goal of “Reactions to learning a ‘not elevated’ amyloid PET result in a preclinical Alzheimer’s disease trial” was to study how learning one is not eligible for a trial based on an Alzheimer’s disease (AD) biomarker result affects willingness to be in subsequent trials, as well as how it affects other behaviors . Answering this question fills a critical gap in the literature, as preclinical AD trials are increasingly common but the ideal criteria for participant inclusion remains an area of active research. Thus, a person ineligible for one trial may be eligible for another.
Joshua D Grill, Jimmy Kwon, Merilee A Teylan, Aimee Pierce, Eric D Vidoni, Jeffrey M Burns, Allison Lindauer, Joseph Quinn, Jeff Kaye, Daniel L Gillen, Bin Nan
2019 Participant retention is important to maintaining statistical power, minimizing bias, and preventing scientific error in Alzheimer disease and related dementias research.
Joshua D Grill, Michelle M Nuño, Daniel L Gillen
2019 Prodromal Alzheimer disease (AD) clinical trials enroll patients with mild cognitive impairment (MCI) meeting biomarker criteria, but specific enrollment criteria vary among trials.